ReviewEXCLI journal2025
MAPK/ERK Signaling in Tumorigenesis: mechanisms of growth, invasion, and angiogenesis.
Review in EXCLI journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- A Prognostic Model Based on Adipokine-Related Genes for Hepatocellular Carcinoma: Assessment of Patient Outcomes and Tumor Microenvironment Characterization.Digestive diseases and sciences · 2026Article
- Agomelatine versus gefitinib against HepG2 cells: Modulating PI3K/AKT and MAPK/RAF1/c-FOS pathways.Molecular biology reports · 2026Article
- A Breg-associated lncRNA signature predicts prognosis and immune landscape in esophageal carcinoma.Translational cancer research · 2026Article
- Genetics and Molecular Mechanisms in Oral Squamous Cell Carcinoma: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Dietary Antioxidants and Redox Signaling in Cancer Prevention: Mechanistic Insights and Metabolic Inflammation.Nutrients · 2026Review
- Targeted Therapy and Immunotherapies in Hepatocellular Carcinoma: Mechanisms and Clinical Studies.MedComm · 2026Review
- Multiomics and multi-region spatial transcriptome analysis reveal cellular networks and pathways associated with HCC recurrence.JHEP reports : innovation in hepatology · 2026Article
- Integrated analysis of Morusin inhibiting esophageal cancer via network pharmacology molecular dynamics simulation and in vitro validation.Discover oncology · 2026Article
- Article
- Article
- Pathophysiological significance of the TRPM2 ion channel as a potential target in cancer, neurological disorders, and ischemia/reperfusion injury.Pharmacological research · 2026Review
- Molecular carcinogenesis and genetic insights in leiomyosarcoma: involvement of PI3K/AKT/mTOR/MAPK/ERK pathway.American journal of cancer research · 2026Review
- More than alternative estrogen receptors: the emerging role of GPER-1 and ERα36 in breast cancer.Exploration of targeted anti-tumor therapy · 2026Review
- Distinct transcriptomic features of tumor and stromal cells in direct contact in luminal and triple-negative breast cancers.Exploration of targeted anti-tumor therapy · 2026Article
- Electrochemical modulation of host-microbe dynamics in wound healing.Frontiers in microbiology · 2026Review
- Article
- Targeting the MAPK Pathway in Cancer.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The significance of ERK1/2 in the process of tumorigenesis has attracted considerable interest owing to its essential role in a variety of cellular mechanisms, especially in relation to cancer initiation and progression. The Ras-Raf-MAPK signaling cascade, responsible for the activation of ERK1/2, plays a vital role in the regulation of tumor cell growth, invasion, and the formation of new blood vessels. Recent research has underscored the intricate nature of the mechanisms by which ERK1/2 is activated and the subsequent implications for tumor biology, illustrating both the oncogenic capabilities and the therapeutic hurdles linked to the modulation of this pathway. Despite progress in the comprehension of ERK1/2 signaling, numerous challenges persist, including the emergence of resistance to therapies that target this pathway, alongside the necessity for more selective inhibitors. This review intends to consolidate the most recent scientific discoveries pertaining to ERK1/2 and its regulatory influence within the Ras-Raf-MAPK pathway, offering insights into how these interactions facilitate tumor proliferation and metastasis. By clarifying the connection between ERK1/2 signaling and tumor biology, this article aspires to contribute to the formulation of novel therapeutic approaches aimed at interrupting this pathway in the context of cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.